Pulse Biosciences

We couldn't be more excited to announce today that Dr. Niv Ad, renowned Cardiothoracic Surgeon, is joining the Pulse Biosciences team as Chief Science Officer, Cardiac Surgery. Dr. Ad is a leading authority in surgical treatment of atrial fibrillation, minimally invasive heart surgery and other advanced heart surgery techniques and transcatheter therapies. Dr. Ad has published more than 200 research articles in peer-reviewed publications. He has led the development of national and international clinical practice guidelines for the different cardiovascular societies for ISMICS, AATS and STS, and serves on multiple leadership positions and committees in the leading cardiothoracic societies. He is the past president of The International Society of Minimally Invasive Cardiothoracic and Vascular Surgery (MICS), the leading entity for minimally invasive procedures globally and he is the Editor in Chief of INNOVATIONS: Technology and Techniques in Cardiothoracic and Vascular Surgery. Welcome to the team Dr. Ad!



Read More: https://lnkd.in/dXjc9NmD

Our proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. nsPFA energy is delivered from the powerful and versatile nsPFA™ generator platform. The nsPFA platform was developed to be capable of connecting to multiple types of applicators from superficial to surgical to catheter-based therapies. Our system has already been used to treat over 6,000 patients safely and effectively outside of Cardiology.

These ultrafast electrical energy pulses have pulse durations from billionths up to a millionth of a second. When applied to targeted tissue, nsPFA energy pulses enter cells and alter the function of the internal cellular organelles, including the mitochondria and endoplasmic reticulum. The cascade of intracellular disruption leads to regulated cell death (RCD). RCD is a process exhibited by cells in the human body when they undergo stress and are unable to restore cellular homeostasis.

Pulse Biosciences has brought to market the first commercial product to harness the distinctive advantages of nsPFA technology.

Pulse Biosciences pioneers in the research, design and production of our patented Nanosecond Pulsed Field Ablation™ (nsPFA™) technology for use in high impact areas of healthcare. We are currently focused on applying this technology within cardiology. We believe there may be several applications in cardiology for nsPFA, including atrial fibrillation.

Nanosecond Pulsed Field Ablation (nsPFA) energy is a novel technology that has the potential to not only help patients with atrial fibrillation, but patients across multiple different therapy areas.